We are testing a new combination treatment for patients with relapsed and refractory t(11;14) multiple myeloma. The goal is to see if this approach improves outcomes compared to current therapies.
Health conditions and diseases that the clinical trial is designed to study and treat.
Relapsed/refractory multiple myeloma is a type of blood cancer that occurs when the disease returns after treatment or does not respond to treatment. It affects plasma cells in the bone marrow, leading to various health issues.
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.